Addition of camrelizumab to docetaxel, cisplatin, and radiation therapy in patients with locally advanced esophageal squamous cell carcinoma: a phase 1b study
Wencheng Zhang, Cihui Yan, Tian Zhang, Xi Chen, Jie Dong, Jingjing Zhao, Dong Han, Jun Wang, Gang Zhao, Fuliang Cao, Dejun Zhou, Hongjing Jiang, Peng Tang, Lujun Zhao, Zhiyong Yuan, Quanren Wang, Ping Wang, Qingsong Pang
Abstract
dendritic cells and peripheral-blood IL-27, IL-15, Eotaxin-3, and IL-22 were associated with OS. First-line concurrent chemoradiotherapy plus camrelizumab had a manageable safety profile and promising antitumour efficacy for ESCC, and deserves further study.
Topics & Concepts
MedicineDocetaxelInternal medicineRadiation therapyOncologyAdverse effectGastroenterologyChemoradiotherapyEsophagitisClinical endpointChemotherapySurgeryClinical trialDiseaseRefluxEsophageal Cancer Research and TreatmentEsophageal and GI PathologyGastric Cancer Management and Outcomes